Strategies to minimize the immunogenicity and toxicity of murine anti-CD3 antibodies (e.g. OKT3) are of special interest for organ transplantation and for the treatment of autoimmune diseases. In the present work, we have developed two humanized anti-CD3 antibodies. These molecules were shown to bind to human CD3, though less efficiently, and display less mitogenic activity than OKT3. These results prompted us to investigate whether this reduced mitogenic potential was associated with the development of anti-inflammatory properties. Indeed, in peripheral blood mononuclear cells (PBMCs), the humanized antibody versions induced a predominantly anti-inflammatory cytokine profile, in contrast with the pro-inflammatory profile induced by OKT3. Neither OKT3 nor the humanized versions induced the expression of IL-4, IL-2 or TGF-beta. Both humanized antibodies induced significantly lower production of IFN-gamma and IL-5 and slightly higher production of IL-10 than OKT3. This immunomodulatory profile was most evident by the 80-fold higher ratio of IL-10/IFN-gamma production in PBMCs cultured in the presence of the humanized antibodies, compared to those stimulated with OKT3. Furthermore, these humanized anti-CD3 antibodies induced a late FOXP3 gene expression while OKT3 led to a more transient expression of FOXP3. Taken our results, we suggest that these humanized anti-CD3 antibodies may promote the development of T cells with immunoregulatory activity.

Dengue virus (DENV) transmission by blood transfusion is an important route of viral acquisition during outbreaks. The prevalence of DENV markers (viral RNA, NS1, anti-DENV IgM, and IgG) among blood donors in Central-West Brazil has never been evaluated. Our aim was to evaluate the full set of serological and molecular markers for DENV among blood donors of the Federal District of Brazil during an extensive outbreak in 2016. We found an anti-DENV IgM prevalence of 6.74% (n = 32/475). Of 475, 20 samples (4.21%) were also anti-DENV IgG positive. All samples were non-reactive for NS1 and DENV RNA. Our results imply that a significant proportion of the tested donors had experienced asymptomatic infection. More studies are necessary to evaluate the real prevalence of DENV viremia in blood donors from the Federal District of Brazil and if specific measures are needed to routinely test the blood donors for DENV RNA during outbreaks.

No abstract

No abstract

Dengue is endemic in Brazil, and several Brazilian cities are affected by frequent seasonal outbreaks of the disease. During the outbreaks the possibility of transfusion-transmitted dengue (TTD) is increased, mainly by the presence of asymptomatic or oligosymptomatic infections in eligible blood donors. The retrospective assessment of anti-DENV IgM and NS1 seroprevalence during a given time interval may indicate the need for measures for the previous screening of DENV infection in blood donors. In this context, we performed retrospective screening for anti-DENV IgM and NS1 in blood donors from the Federal District of Brazil during the early outbreak that occurred in 2019, the largest outbreak in recent years. In total, 450 blood donations were screened for anti-DENV IgM and DENV NS1 using commercial enzyme-linked immunosorbent assay kits (Panbio Dengue IgM Capture ELISA and Platelia Dengue NS1 Ag, respectively). Among the tested plasma samples, 16 % (72/450) presented anti-DENV IgM; no samples presented DENV NS1. Despite the apparent absence of antigenaemia in tested blood donations, the high prevalence of anti-DENV IgM highlights the importance of DENV screening in blood donors, principally during outbreak periods.